Probiotic *Lactobacillus gasseri* SBT2055 improves glucose tolerance and reduces body weight gain in rats by stimulating energy expenditure

Bungo Shirouchi1, Koji Nagao2, Minami Umegatani1, Aya Shiraishi1, Yukiko Morita1, Shunichi Kai2, Teruyoshi Yanagita3, Akihiro Ogawa4, Yukio Kadooka4 and Masao Sato1*

1Laboratory of Nutrition Chemistry, Department of Bioscience and Biotechnology, Faculty of Agriculture, Graduate School, Kyushu University, 6-10-1 Hakozaki, Higashi-ku, Fukuoka 812-8581, Japan
2Laboratory of Nutrition Biochemistry, Department of Applied Biochemistry and Food Science, Saga University, I Honjo, Saga 840-8502, Japan
3Faculty of Health and Nutrition Science, Nishikyushu University, 4490-9 Ozaki, Kanzaki, Saga 842-8585, Japan
4Milk Science Research Institute, Megmilk Snow Brand Co. Ltd, 1-1-2 Minamidaiti, Kawage, Saitama 350-1165, Japan

(Submitted 22 December 2015 – Final revision received 28 April 2016 – Accepted 30 April 2016 – First published online 8 June 2016)

Abstract
Probiotic *Lactobacillus gasseri* SBT2055 (LG2055) reduces postprandial TAG absorption and exerts anti-obesity effects in rats and humans; however, the underlying mechanisms are not fully understood. In the present study, we addressed the mechanistic insights of the anti-obesity activity of LG2055 by feeding Sprague–Dawley rats diets containing skimmed milk fermented or not by LG2055 for 4 weeks and by analysing energy expenditure, glucose tolerance, the levels of SCFA in the caecum and serum inflammatory markers. Rats fed the LG2055-containing diet demonstrated significantly higher carbohydrate oxidation in the dark cycle (active phase for rats) compared with the control group, which resulted in a significant increase in energy expenditure. LG2055 significantly reduced cumulative blood glucose levels (AUC) compared with the control diet after 3 weeks and increased the molar ratio of butyrate:total SCFA in the caecum after 4 weeks. Furthermore, the LG2055-supplemented diet significantly reduced the levels of serum amyloid P component – an indicator of the inflammatory process. In conclusion, our results demonstrate that, in addition to the inhibition of dietary TAG absorption reported previously, the intake of probiotic LG2055 enhanced energy expenditure via carbohydrate oxidation, improved glucose tolerance and attenuated inflammation, suggesting multiple additive and/or synergistic actions underlying the anti-obesity effects exerted by LG2055.

Key words: *Lactobacillus gasseri* SBT2055: Energy expenditure: Glucose tolerance: Obesity

The use of probiotic strains such as lactobacilli and bifidobacteria is increasingly expanding because of their beneficial effects(1). *Lactobacillus gasseri* SBT2055 (LG2055) is a representative of probiotic lactic acid bacteria isolated from the gastrointestinal tract in Japan(2,3), which has been shown to improve intestinal microflora and metabolism(4). Previous studies have indicated that LG2055 decreases lymphatic TAG absorption and increases faecal fatty acid excretion in rats(5), decreases postprandial TAG absorption in humans(6) and exerts anti-obesity effect both in animals(7–20) and in humans(20,21). However, the underlying mechanisms are not quite clear. Other probiotic bacteria have also been reported to improve metabolism and exert anti-obesity effects in rodents(12–25). The key mechanisms include induction of lipolysis via production of *trans*-10,cis-12-conjugated linoleic acid(12,13), increase in sympathetic nerve activity(14) and suppression of fat deposition via increased expression of angiopoietin-like 4, a circulating inhibitor of lipoprotein lipase(15,17). Furthermore, several *Lactobacillus* strains have been shown to induce transcriptional activation of fatty acid β-oxidation-related genes in the liver(19–21,25) and muscle(21), while inhibiting the transcription of fatty acid synthase in the liver(24), and to improve insulin sensitivity(21,22) and glucose tolerance(25). However, there is no direct evidence of the effects of probiotics on energy expenditure, which is closely related to the metabolism of macronutrients, especially carbohydrates and fats.

Obesity develops as a consequence of chronic deregulation in macronutrient oxidation levels(26,27). Therefore, to gain the mechanistic insights of anti-obesity effects exerted by LG2055, it is necessary to evaluate the relationship between energy and macronutrient metabolism. Several methods have been used to assess the balance between nutrient oxidation and energy generation, such as indirect calorimetry, which has been applied to estimate net rates of carbohydrate and fat oxidation in humans(26,20) and rodents(29,30) based on VO2 and carbon

Abbreviations: CRP, C-reactive protein; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide-1; GPR41, G protein-coupled receptors 41; SAP, serum amyloid P component; SM, skimmed milk.

* Corresponding author: M. Sato, fax +81 92 642 3004, email masaos@agr.kyushu-u.ac.jp
dioxide production. Another widely used convenient and reliable method is the oral glucose tolerance test (OGTT), which can help diagnose glucose intolerance and insulin resistance(31).

Obesity is a part of the metabolic syndrome, which, according to previous reports, is associated with low-grade inflammation, shown to play a role in the pathogenesis of glucose disorders(32,33). Thus, insulin resistance and type 2 diabetes are induced by high sucrose and lard rich in SFA were used to induce obesity and glucose intolerance.

In the present study, we addressed the mechanistic insights of LG2055-fermented SM powder (LG2055 diet), 125 casein, 150 α-maize starch, 50 cellulose, 3 DL-methionine, 35 mineral mixture (AIN-76), 10 vitamin mixture (AIN-76) and sucrose to prepare the diets according to the AIN formulae:

\[
RQ = \frac{VCO_2}{VO_2},
\]

\[
\text{carbohydrate oxidation} = 4.51 \times VCO_2 - 3.18 \times VO_2,
\]

\[
\text{fat oxidation} = 1.67 \times (VCO_2 - VO_2),
\]

\[
\text{energy production rate} = (2.96 \times RQ + 2.49) \times VO_2,
\]

where \(VCO_2\) is carbon dioxide exhaustion.
During the analysis, rats were pair-fed diets and had free access to water. The experiment was carried out in a separate room to avoid animal stress.

**Oral glucose tolerance test**

After 3 weeks of feeding, rats were subjected to 16 h of fasting and then orally administered a glucose bolus (2 g/kg body weight). Blood was drawn from the tail vein at 0, 15, 30, 60, 90 and 120 min after bolus administration, and glucose levels were measured using an Accu-Chek® Aviva Nano blood glucose meter (Roche Diagnostics). The AUC of blood glucose concentration (0–120 min) was calculated using the trapezoidal rule.

**Analysis of metabolic parameters**

The levels of blood HbA1c were measured using a commercial kit based on the latex-agglutination assay (RAPIDIA® Auto HbA1c-1; Fujirebio Inc.). Plasma TAG, cholesterol, free fatty acids and glucose levels were measured using enzyme assay kits (Triglyceride E-Test, Cholesterol E-Test, NEFA C-Test and Glucose CII-Test, respectively; Wako Pure Chemicals). Plasma levels of insulin, glucagon, glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 and serum levels of fatty acid-binding protein 4 (FABP4) and SAP were measured using commercial ELISA kits (rat insulin ELISA; Shibayagi Co. Ltd, rat/ mouse GIP total ELISA; EMD Millipore Co., rat glucagon ELISA kit and rat GLP-1 ELISA kit; Wako Pure Chemicals, CircuLex Rat FABP4/A-FABP ELISA kit; CycLex Co. Ltd, Serum Amyloid P Rat ELISA kit; Abcam). Glycogen levels in the liver and muscle were determined according to the method of Lo et al.(37).

**Analysis of caecal lactic acid and SCFA**

The caecal levels of lactic acid and SCFA were determined as described elsewhere(38) with some modifications. In brief, caecal content was homogenised in sterile water, de-proteinised with 60% HClO4 and separated by centrifugation at 8500 g for 10 min at 4°C. The supernatant was filtered through a cellulose acetate membrane filter (0.45 μm; Advantec), and individual SCFA were determined by the bromothymol blue (BTB) post-column method using an HPLC system (SHIMADZU SCL-10A; Shimadzu). The analytical conditions were as follows: column, TSKgel OApak-A (7 μm, 7.8 mm i.d.×30 cm; Tosoh Co.); guard column, TSKgel OApak-P (10 μm, 6.0 mm i.d.×4 cm; Tosoh Co.); eluent and flow rate, 5 ml·HClO4 at 0.7 ml/min; column temperature, 60°C; reagents and flow rate, 0.1 ml·BTB and 15 ml·Na2HPO4 at 1.2 ml/min; and detector wavelength, 445 nm. The injection volume was 25 μl, and the total run time was 40 min. Total SCFA present the sum of acetate, propionate and butyrate levels.

**Statistical analysis**

All values are expressed as means with their standard errors. Differences between the two groups were determined by Student’s t test and were considered statistically significant at \( P < 0.05 \).

**Results**

**Effects of the LG2055 diet on nutrient oxidation and energy expenditure**

The effects of the LG2055 diet on energy metabolism were assessed on the basis of respiratory gas analysis in rats fed the same amount of diets (control group, 10·7 (SEM 0·1) g; LG2055 group, 10·8 (SEM 0·1) g). The LG2055 group demonstrated significantly higher carbohydrate oxidation in the dark cycle (active phase for rats) compared with the control group, which resulted in a significant increase in energy expenditure (Fig. 1(a) and (c)). Moreover, the LG2055 diet tended to induce fat oxidation in the light cycle (resting phase for rats) (Fig. 1(b)), although the effect was not statistically significant.

**Effects of the LG2055 diet on morphometric and metabolic parameters**

The two groups of rats did not differ in their food intake after the 4-week feeding period. Body weight gain was significantly lower in the LG2055 diet-fed rats (Table 1). However, there were no differences between the two groups in terms of organ weights (liver, quadriceps femoris, pancreas, caecum and WAT), plasma parameters (TAG, cholesterol, free fatty acid, glucose, insulin, glucagon, GIP and GLP-1), blood HbA1c, serum FABP4 and glycogen content of the liver and muscle (Table 1). At the same time, SAP levels were significantly reduced in the LG2055 diet-fed rats. Table 2 shows that the contents of lactic acid, the ratios of acetate:total SCFA and propionate:total SCFA in the caecum did not differ between the two groups, but the propionate + butyrate:total SCFA ratio tended to be higher (\( P=0.085 \)) and the butyrate:total SCFA ratio was significantly higher (\( P<0.05 \)) in the LG2055 group. Total butyrate content in the caecum also tended to increase (7.02 (SEM 1.08) μmol/g in the control group v. 8.58 (SEM 0.46) μmol/g in the LG2055 group), but the difference was not statistically significant.

**Effects of the LG2055 diet on postprandial glucose responses**

OGTT analysis indicated that the LG2055 diet tended to lower postprandial glucose levels in rats starting 15 min after bolus challenge compared with the control diet, resulting in a significant decrease in cumulative glucose levels (AUC, \( P<0.05 \); Fig. 2 inset).

**Discussion**

In the present study, we addressed the mechanistic insights of anti-obesity effects exerted by the probiotic lactic acid bacteria strain *L. gasseri* SBT2055. The results indicated that LG2055 enhanced energy expenditure and improved glucose tolerance,
which correlates with previously shown reduction in post-prandial TAG absorption\(^{(5,6)}\). We believe that the enhancement of energy expenditure via increase in carbohydrate oxidation (Fig. 1(a) and (c)) may have contributed to the LG2055-elicited anti-obesity effect (Table 1) and improvement in glucose tolerance (Fig. 2). Mammals utilise not only glucose, long-chain fatty acids and amino acids as energy sources, but also SCFA derived from colonic fermentation of dietary fibre by the gut microbiota. The association of microbial activity in the gastrointestinal tract with host energy homeostasis and obesity pathogenesis is increasingly recognised\(^{(39,40)}\). Recently, a series of orphan G protein-coupled receptors were shown to bind free fatty acids; among them, free fatty acid receptor 3 (FFA3/GPR41) is expressed in the intestine and sympathetic nervous system, and is activated by SCFA\(^{(41)}\) including propionate (C3) and butyrate (C4), which showed 9.6-fold and 11.9-fold higher receptor activation compared with acetate (C2)\(^{(42)}\). GPR41 knockout mice exhibited lower energy expenditure and glucose tolerance compared with wild-type mice\(^{(43)}\). Kimura et al.\(^{(44)}\) reported that SCFA directly up-regulate the activity of the sympathetic nervous system via GPR41, and thereby enhance body energy expenditure in mice. In addition, Gao et al.\(^{(45)}\) reported that dietary supplementation of sodium butyrate improves insulin sensitivity and increases energy expenditure in mice. In the present study, the LG2055 diet tended to increase the content of caecal butyrate and decrease that of acetate, which is less potent in GPR41 activation, resulting in a significantly elevated (39.4 %) ratio of butyrate: total SCFA (Table 2). These results suggest that the increase in butyrate production in the caecum by LG2055 may enhance energy expenditure and improve glucose tolerance via GPR41 activation. Further controlled studies are needed to determine whether and how changes in SCFA profile of the caecum by LG2055 are reflected in SCFA levels of portal and aortic sera, and whether GPR41 is activated by LG2055. Considering that other probiotic bacteria also inhibit obesity development in rodents\(^{(12–25)}\), it should be interesting to investigate whether their anti-obesity effects are associated with the enhancement of butyrate production. Furthermore, it is known that incretin hormones such as GIP and GLP-1 control energy metabolism\(^{(46)}\). Tolhurst et al.\(^{(47)}\) reported that SCFA stimulate GLP-1 secretion via GPR41 in primary mouse colonic cells. Moreover, incretin hormones are released from the intestine in response to food ingestion\(^{(46)}\). However, in the present study, plasma levels of GIP and GLP-1 after 9 h of fasting did not differ between the groups (Table 1). These results may reflect that unlike prebiotics, the change of SCFA profile by probiotics is milder.

Probiotics and prebiotics affect fermentation processes in the host caecum and regulate SCFA synthesis. Several studies have demonstrated that consumption of a diet high in inulin\(^{(48)}\), oligofructose\(^{(49)}\) or their combination\(^{(50)}\) reduced body weight by lowering energy intake in rats. Dietary prebiotic fibres containing inulin and oligofructose in a 1:1 ratio altered energy intake by increasing satiety hormones but not energy expenditure; however, as caecal SCFA levels were not measured in that study\(^{(50)}\), the contribution of SCFA to the reduction of body weight by prebiotics remains unclear. Together, these findings indicate that the reduction of

Fig. 1. Time course of the changes in carbohydrate oxidation (a), fat oxidation (b) and energy expenditure (c) in rats fed the control (○—○—) diet or the LG2055 (■—■—) diet for 1 week. Values are means (n = 6), with their standard errors. * Mean values were significantly different from those of the control group (P < 0.05). BW, body weight.
body weight by dietary fibres depends on energy intake rather than energy expenditure, suggesting that prebiotics and probiotics may prevent obesity through distinct mechanisms. Therefore, diet supplementation with a mixture of probiotics and prebiotics (synbiotics) may exert more powerful anti-obesity effects due to synergism in SCFA production with the change in intestinal flora and should be a focus of future studies.

It has been proposed that low-grade inflammation is a feature of the metabolic syndrome, which may be promoted by the release of various inflammatory mediators from adipose tissue\(^{32}\). Previous cross-sectional studies have shown that insulin resistance and type 2 diabetes are associated with higher levels of pro-inflammatory cytokines and acute-phase reactants such as C-reactive protein (CRP)\(^{34,35}\), which is consistent with the observation that lipopolysaccharide (LPS) presence results in increased inflammatory mediators from adipose tissue\(^{34,35}\).

### Table 1. Effects of diets containing skimmed milk (control) and fermented milk (LG2055) on morphometric and metabolic parameters of rats (Mean values with their standard errors)

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>SEM</th>
<th>LG2055</th>
<th>SEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Food intake (g/d)</td>
<td>20.6 ± 0.2</td>
<td></td>
<td>20.6 ± 0.2</td>
<td></td>
</tr>
<tr>
<td>Body weight gain (g)</td>
<td>175 ± 7</td>
<td></td>
<td>157 ± 4*</td>
<td></td>
</tr>
<tr>
<td>Mass (g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>10.5 ± 0.8</td>
<td></td>
<td>10.7 ± 0.5</td>
<td></td>
</tr>
<tr>
<td>Quadriceps femoris</td>
<td>4.88 ± 0.23</td>
<td></td>
<td>4.72 ± 0.30</td>
<td></td>
</tr>
<tr>
<td>Pancreas</td>
<td>0.631 ± 0.058</td>
<td></td>
<td>0.554 ± 0.019</td>
<td></td>
</tr>
<tr>
<td>Caecum with contents</td>
<td>3.31 ± 0.27</td>
<td></td>
<td>2.83 ± 0.11</td>
<td></td>
</tr>
<tr>
<td>White adipose tissues</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mesenteric</td>
<td>3.64 ± 0.25</td>
<td></td>
<td>3.20 ± 0.22</td>
<td></td>
</tr>
<tr>
<td>Perirenal</td>
<td>1.23 ± 0.17</td>
<td></td>
<td>1.16 ± 0.20</td>
<td></td>
</tr>
<tr>
<td>Retroperitoneal</td>
<td>4.31 ± 0.26</td>
<td></td>
<td>4.47 ± 0.69</td>
<td></td>
</tr>
<tr>
<td>Epididymyal</td>
<td>5.00 ± 0.36</td>
<td></td>
<td>4.63 ± 0.58</td>
<td></td>
</tr>
<tr>
<td>Subcutaneous</td>
<td>13.0 ± 0.9</td>
<td></td>
<td>12.5 ± 1.3</td>
<td></td>
</tr>
<tr>
<td>Blood HbA1c (%)</td>
<td>6.64 ± 0.73</td>
<td></td>
<td>6.26 ± 0.41</td>
<td></td>
</tr>
<tr>
<td>Plasma parameters</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TAG (mg/l)</td>
<td>1053 ± 251</td>
<td></td>
<td>1425 ± 190</td>
<td></td>
</tr>
<tr>
<td>Cholesterol (mg/l)</td>
<td>648 ± 80</td>
<td></td>
<td>666 ± 89</td>
<td></td>
</tr>
<tr>
<td>Free fatty acid (mEq/l)</td>
<td>0.394 ± 0.052</td>
<td></td>
<td>0.464 ± 0.049</td>
<td></td>
</tr>
<tr>
<td>Glucose (mg/l)</td>
<td>2220 ± 139</td>
<td></td>
<td>2139 ± 126</td>
<td></td>
</tr>
<tr>
<td>Insulin (ng/ml)</td>
<td>4.48 ± 0.81</td>
<td></td>
<td>5.04 ± 1.9</td>
<td></td>
</tr>
<tr>
<td>Glucagon (pg/ml)</td>
<td>557 ± 87</td>
<td></td>
<td>544 ± 75</td>
<td></td>
</tr>
<tr>
<td>GIP (pg/ml)</td>
<td>74.7 ± 11.8</td>
<td></td>
<td>74.8 ± 7.1</td>
<td></td>
</tr>
<tr>
<td>GLP-1 (ng/ml)</td>
<td>2.92 ± 0.61</td>
<td></td>
<td>3.66 ± 0.54</td>
<td></td>
</tr>
<tr>
<td>Serum FABP4 (ng/ml)</td>
<td>586 ± 133</td>
<td></td>
<td>533 ± 84</td>
<td></td>
</tr>
<tr>
<td>Serum amyloid P component (µg/ml)</td>
<td>192 ± 6</td>
<td></td>
<td>165 ± 8*</td>
<td></td>
</tr>
<tr>
<td>Liver glycogen (mg/whole liver)</td>
<td>259 ± 54</td>
<td></td>
<td>275 ± 86</td>
<td></td>
</tr>
<tr>
<td>Muscle glycogen (mg/whole quadriceps femoris)</td>
<td>2.26 ± 0.20</td>
<td>2.70 ± 0.36</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

HbA1c, glycated Hb; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide-1; FABP4, fatty acid-binding protein 4.

* Mean values were significantly different from those of the control group (P<0.05).

### Table 2. Effects of diets containing skimmed milk (control) and fermented milk (LG2055) on caecal lactic acid contents, caecal SCFA contents and molar SCFA ratios in rats† (Mean values with their standard errors)

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>SEM</th>
<th>LG2055</th>
<th>SEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Caecal lactic acid (µmol/g content)</td>
<td>2.34 ± 0.60</td>
<td>2.16 ± 0.33</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caecal SCFA (µmol/g content)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acetate</td>
<td>62.5 ± 7.7</td>
<td></td>
<td>51.7 ± 4.6</td>
<td></td>
</tr>
<tr>
<td>Propionate</td>
<td>15.3 ± 1.4</td>
<td></td>
<td>15.5 ± 1.0</td>
<td></td>
</tr>
<tr>
<td>n-Butyrate</td>
<td>7.02 ± 1.08</td>
<td></td>
<td>8.58 ± 0.46</td>
<td></td>
</tr>
<tr>
<td>Propionate + n-butyrate</td>
<td>22.3 ± 2.3</td>
<td></td>
<td>24.1 ± 1.2</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>84.7 ± 8.6</td>
<td></td>
<td>75.8 ± 5.5</td>
<td></td>
</tr>
<tr>
<td>Molar SCFA ratio (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acetate:total SCFA</td>
<td>73.3 ± 2.5</td>
<td></td>
<td>67.8 ± 1.6</td>
<td></td>
</tr>
<tr>
<td>Propionate:total SCFA</td>
<td>18.5 ± 1.8</td>
<td></td>
<td>20.7 ± 1.2</td>
<td></td>
</tr>
<tr>
<td>n-Butyrate:total SCFA</td>
<td>8.25 ± 1.04</td>
<td></td>
<td>11.5 ± 0.7*</td>
<td></td>
</tr>
<tr>
<td>Propionate + n-butyrate:total SCFA</td>
<td>26.7 ± 2.5</td>
<td>32.2 ± 1.6</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

† Total SCFA (acetate, propionate and n-butyrate).

* Mean values were significantly different from those of the control group (P<0.05).
in the amplification of inflammatory cascades via CRP production\(^\text{55}\). Therefore, circulating CRP levels are used as a biomarker to assess inflammatory status\(^\text{52}\). However, in rats, serum CRP concentration is much higher compared with other species, exceeding even its maximal acute phase levels in humans\(^\text{53}\), which precludes the use of rat models in studies of CRP-associated inflammatory mechanisms. SAP is an acute-phase protein, which shares approximately 60% homology with CRP\(^\text{53,54}\) and has comparable serum levels in rats and humans. Besides, rat SAP does not function as an acute-phase reactant in response to exogenous inflammatory stimuli such as casein or croton-oil injections\(^\text{53}\), which is similar to human but different from mouse SAP\(^\text{53}\), suggesting that the findings in rats can be extrapolated to humans. SAP binds to gram-negative bacteria expressing LPS\(^\text{55,56}\), indicating that SAP levels are indices for infection of gram-negative bacteria and LPS influx into the body. Several studies have shown that low-grade inflammation is defined as a 2- to 4-fold increases in circulating inflammatory acute-phase proteins\(^\text{57,58}\). The normal range of SAP in rat and human sera is 10–50 μg/ml\(^\text{53,54}\). In the present study, we found that the LG2055 diet significantly reduced serum levels of SAP (192 (SEM 6) μg/ml in the control group vs. 165 (SEM 8) μg/ml in the LG2055 group), suggesting that LG2055 can prevent low-grade inflammation associated with obesity and glucose metabolism disorders.

In conclusion, we found that, in addition to the inhibition of dietary TAG absorption reported previously, probiotic LG2055 enhanced energy expenditure via stimulation of carbohydrate oxidation, improved glucose tolerance and reduced the levels of pro-inflammatory mediator SAP in rats. Considering that these effects correlate with the reduction of body weight gain, our findings suggest multiple actions activated by LG2055 that may work in synergy to prevent obesity.

Acknowledgements

The authors thank Editage (www.editage.jp) for English language editing.

The study was supported by Megmilk Snow Brand Co. Ltd (Saitama, Japan). The cost of English language editing was supported by a Research Grant for Young Investigators of Faculty of Agriculture, Kyushu University.

B. S. wrote the manuscript. B. S., K. N., M. U., A. S., Y. M. and S. K. carried out the experimental work and collected and analysed the data. B. S., K. N., T. Y., A. O., Y. K. and M. S. contributed to the study design, supervised the study and commented on the manuscript. All authors have read and approved the final version of the manuscript.

A. O. and Y. K. are employees of Megmilk Snow Brand Co. Ltd. There are no other patents, products in development or marketed products to declare. All other authors have no conflicts of interest to declare.

References


Effects of LG2055 on energy expenditure


